Topic: CogSim/AI/ML Hardware

Increased resource utilization is one goal of new architectures. At Livermore Computing, these include AI accelerators such as Samba Nova and Cerebras systems and El Capitan's Rabbits.

In a milestone for supercomputing-aided drug design, LLNL and BridgeBio Oncology Therapeutics today announced clinical trials have begun for a first-in-class medication that targets specific genetic mutations implicated in many types of cancer.

LLNL’s fusion ignition breakthrough, more than 60 years in the making, was enabled by a combination of traditional fusion target design methods, HPC, and AI techniques.

Can novel mathematical algorithms help scientific simulations leverage hardware designed for machine learning? A team from LLNL’s Center for Applied Scientific Computing aimed to find out.

The report lays out a comprehensive vision for the DOE Office of Science and NNSA to expand their work in scientific use of AI by building on existing strengths in world-leading high performance computing systems and data infrastructure.

LLNL CTO Bronis de Supinski talks about how the Lab deploys novel architecture AI machines and provides an update on El Capitan.

As CTO of Livermore Computing, de Supinski is responsible for formulating, overseeing, and implementing LLNL’s large-scale computing strategy, requiring managing multiple collaborations with the HPC industry and academia.

The addition of the spatial data flow accelerator into LLNL’s Livermore Computing Center is part of an effort to upgrade the Lab’s cognitive simulation (CogSim) program.

Adding machine learning and other artificial intelligence methods to the feedback cycle of experimentation and computer modeling can accelerate scientific discovery.